France’s largest independent pharmaceutical company is not publicly traded and never will be. Governed by a non-profit foundation (FIRS), Servier has spent seven decades building a global presence across 130+ countries. In FY2024–25, revenue reached €6.9 billion ($7,452 million), powered by a radical strategic pivot: 70 per cent of R&D spending now goes into oncology.
There are two kinds of pharmaceutical companies in the world: those that answer to shareholders every quarter, and those that do not. Servier belongs to the second category, and the distinction is not cosmetic. The company is governed by the Fondation Internationale de Recherche Servier (FIRS), a non-profit foundation established to ensure that the company’s mission outlives any individual leader. There are no external shareholders. There are no quarterly earnings calls. There is no activist investor demanding a share buyback.
This structure, which Servier shares with Boehringer Ingelheim and a handful of other European pharma companies, enables decisions that public companies struggle to make. When Servier decided to pivot its R&D spending from cardiometabolism to oncology, it could do so without explaining to Wall Street why short-term margins would compress. When it invested in a new R&D Institute at Paris-Saclay, staffing it with 1,200 researchers by FY2022–23, it did not need to justify the capital expenditure against next quarter’s earnings per share.
Founded in 1954, Servier celebrated its 70th anniversary in 2024. In those seven decades, the company grew from a French cardiovascular specialist into a global pharmaceutical group present in more than 130 countries with 20,000 employees. The foundation model did not guarantee success, but it removed one of the most common obstacles to long-term thinking in the pharmaceutical industry: the tyranny of the quarterly report.
For most of its history, Servier was a cardiometabolism company. It was the third-largest pharmaceutical group globally in that therapeutic area, with a portfolio of cardiovascular and diabetes medicines that generated steady, predictable revenue across its 130+ country footprint. The cardiometabolism franchise was the company’s identity. It was also, increasingly, its limitation.
The strategic bet Servier made in the 2010s was as audacious as anything in the pharmaceutical industry: take a company known for heart and diabetes drugs, and redirect 70 per cent of its R&D budget into oncology. This was not a diversification play. It was a transformation. Servier acquired oncology assets, built oncology clinical development capabilities from near-zero, and hired oncologists and tumour biologists who had never heard of the company’s cardiovascular heritage.
By FY2024–25, the pivot had begun producing measurable results. The company’s pipeline contained 62 R&D projects, a portfolio breadth that would be respectable for a company twice its size. Revenue had grown from $5,076 million in FY2020–21 to $7,452 million in FY2024–25, a 47 per cent increase in four years. And the growth was accelerating: the jump from $6,374 million to $7,452 million in a single year represented the steepest annual increase in the company’s history. The oncology pipeline had not yet fully matured. But the revenue line was already moving.
The physical manifestation of Servier’s reinvention sits on the Paris-Saclay campus south of Paris, in one of Europe’s densest clusters of scientific research. The Servier R&D Institute that opened there brought 1,200 researchers under one roof by FY2022–23, creating a critical mass of drug discovery and development capability that Servier had previously distributed across multiple smaller sites.
The investment was characteristic of foundation-governed decision-making. A publicly traded company with $5.3 billion in revenue (as Servier had in FY2021–22) would face uncomfortable questions from analysts about the return on a major real estate and R&D centralisation project. Servier did not have to answer those questions. It built the campus because the science required proximity, and because the 62-project pipeline demanded the kind of interdisciplinary collaboration that only physical co-location can reliably produce.
Beyond oncology, Servier maintained active programmes in cardiometabolism (where it remained the world’s third-largest player), venous diseases, and neurology. The therapeutic breadth was deliberate. While 70 per cent of R&D spending went to oncology, the remaining 30 per cent sustained the cardiovascular and metabolic franchises that still generated the majority of the company’s revenue. The mature products funded the transformation. The transformation, in time, would replace them.
Servier is probably the largest pharmaceutical company that most people outside the industry have never heard of. With $7.5 billion in revenue and presence in more than 130 countries, it is larger than many publicly listed pharma companies that receive far more attention. The anonymity is partly structural: foundation-governed companies do not hold investor days, do not issue press releases timed to market hours, and do not employ investor relations teams to manage analyst expectations.
But the anonymity is also strategic. Servier operates in markets from Western Europe to sub-Saharan Africa to Southeast Asia, reaching patients through a commercial infrastructure that has been built over seven decades. In many of these markets, Servier is a significant presence in cardiovascular medicine. The company does not seek headlines. It seeks prescriptions. With 22,000 employees in FY2023–24 (trimmed to 20,000 by FY2024–25 as part of the ongoing reorganisation), Servier maintains a workforce that is lean relative to its geographic footprint. The efficiency is a function of the foundation model: without dividend obligations to external shareholders, more of each euro of revenue can be reinvested in the business.
Sources: Servier Group Annual Reports FY2019–20 through FY2024–25. Servier corporate disclosures. OPPI member directory.